Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.

Vadim S. Koshkin,Yilun Sun,Dory Freeman,Chelsea K. Osterman,Christopher Su,Divya Natesan,Ali Raza Khaki,Dimitrios Makrakis,Jayanshu Jain,Anders Olsen,Arnab Basu,Pedro C. Barata,Yousef Zakharia,Mehmet Asim Bilen,Hamid Emamekhoo,Nancy B. Davis,Matthew I. Milowsky,Deepak Kilari,Guru Sonpavde,Ajjai Alva

Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.

2021

443Background: Enfortumab vedotin (EV) is an antibody-drug conjugate targeting Nectin-4, which is FDA approved for patients (pts) with treatment-refractory advanced urothelial cancer (aUC). The act...

Keywords:

Oncology
urothelial cancer
Enfortumab vedotin
Medicine
retrospective analysis
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations